Metastatic Breast Cancer
Conditions
Keywords
Breast cancer, HER2-positive, Metastases
Brief summary
In HER2-positive metastatic breast cancer, trastuzumab based treatment is the standard of care as long as there are no contraindications to trastuzumab. Frequently, trastuzumab is being combined with taxanes in the first-line setting. However, since therapy with trastuzumab is active even in the absence of chemotherapy in HER2-positive MBC, the optimal treatment strategy either in combination or in sequence with chemotherapy is still under debate. This randomized phase II trial is studying a new strategy for the treatment of metastatic breast cancer with HER2-positive. First-line treatment consists of trastuzumab and pertuzumab, a treatment without chemotherapy. In case of disease progression, chemotherapy with T-DM1 is then performed as second-line treatment. Third-line and further line therapies are performed according to the physician's discretion. If this new therapeutic strategy is as effective and better tolerated than the conventional strategy, this would mean a serious breakthrough in the treatment of HER2-positive metastatic breast cancer.
Detailed description
OBJECTIVES: Primary -To evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) and of a chemotherapy-containing dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) in patients with HER2-positive metastatic breast cancer. Secondary * To evaluate other efficacy parameter * To evaluate the safety and tolerability profile of the two treatment strategies * To evaluate the Quality of Life (QoL) * To learn how patients are treated after trial treatment OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor status (positive vs negative), prior trastuzumab (never or \>12 months vs ≤12 months after last infusion), visceral metastases (present vs absent) and site. Patients are randomized to 1 of 2 treatment arms.
Interventions
DRUGTrastuzumab
First administration (loading dose) 8 mg/kg i.v. infusion over 90 min. \- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.
DRUGPertuzumab
First administration (loading dose) 840 mg i.v. infusion over 60 min. \- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.
DRUGPaclitaxel
Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
DRUGVinorelbine
First administration: Day 1 and 8 25 mg/m2 i.v. infusion * then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion
DRUGT-DM1
Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
Sponsors
Swiss Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
SELECTION OF PATIENTS (MOST IMPORTANT CRITERIA) Inclusion criteria for first-line therapy • Histologically confirmed breast cancer with distant metastases Note: 1. A biopsy from the primary tumor or a metastasis can be used for diagnosis. 2. Patients with non-measurable lesions are eligible. 3. Patients with inoperable, locally advanced breast cancer with lymph node metastases other than ipsilateral locoregional (axillary, infraclavicular, parasternal) or other distant metastases are eligible. 4. Patients with bone metastases with or without bone targeted therapy (bisphosphonates, denosumab) are eligible. 5. Patients with de-novo Stage IV disease are eligible. * HER2-positive tumor according to central pathology testing for HER2 Note: 1. A formalin-fixed paraffin-embedded (FFPE) biopsy from the primary tumor or a metastasis has to be used for HER2 status determination. If a biopsy is available from a metastasis, the HER2 testing should be performed using the metastasis. 2. Fine needle aspiration is not acceptable for HER 2 testing. • Women aged ≥18 years • WHO performance status 0 to 2 * Left Ventricular Ejection Fraction (LVEF) ≥50% as determined by either ECHO or MUGA * Adequate organ function, evidenced by the following laboratory results: Neutrophils \>1.5x109/L, platelets \>100x109/L, hemoglobin ≥90g/L, total bilirubin ≤1.5xULN (unless the patients has documented Gilbert's disease), AST ≤3xULN, ALT ≤3xULN, AP ≤2.5xULN (except in patients with bone metastases: AP ≤5xULN), creatinine ≤1.5xULN
Exclusion criteria
for first-line therapy • Prior chemotherapy for inoperable locally advanced or metastatic breast cancer Note: Prior neoadjuvant/adjuvant chemotherapy is allowed if doses for anthracyclines have not exceeded 720mg/m2 and 240mg/m2 for epirubicin and doxorubicin, respectively. \- Re-exposure to paclitaxel is permitted, if the last dose of taxane was given at least 1 year before randomization. \- Re-exposure to vinorelbine is permitted, if the last dose of vinorelbine was given at least 1 year before randomization. * Prior anti-HER2 treatment for metastatic or inoperable breast cancer Note: Prior neoadjuvant/adjuvant anti-HER2 treatment with trastuzumab and/or lapatinib is allowed. • More than one endocrine treatment line for metastatic or inoperable breast cancer exceeding a duration of 1 month Note: <!-- --> 1. Adjuvant endocrine treatment is not counted as one line. 2. Patients progressing on endocrine treatment: this specific endocrine treatment must have been stopped at least 2 weeks prior to randomization. • Prior treatment with pertuzumab and/or T-DM1 • Known leptomeningeal or CNS metastases Note: A brain MRI or CT scan is mandatory in case of clinical suspicion of CNS metastases. • Single bone metastasis treated with radiotherapy (if the bone metastasis is the only tumor lesion) Inclusion criteria for second-line therapy • At least one dose of trial therapy in the first-line treatment phase of this trial • • Proven disease progression on first-line therapy or radiotherapy of a bone metastasis Notes: First new parenchymal CNS metastases only do not count as progression requiring the initiation of second line trial treatment. Radiotherapy of a single area only for pain control is allowed and will not count as PD. • Adequate organ function, evidenced by the following laboratory results: Neutrophils \>1.5x109/L, platelets \>100x109/L, hemoglobin ≥90g/L, total bilirubin ≤1.5xULN (unless the patients has documented Gilbert's disease), AST ≤3xULN, AP ≤2.5xULN (except in patients with bone metastases: AP ≤5xULN), creatinine ≤1.5ULN • LVEF ≥50% as determined by either ECHO or MUGA • QoL questionnaire has been completed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) - Analysis Population: ITT Population 1 | 24 months | Patients being alive 24 months after randomization. A success is considered if a patient is alive at least 24 months after randomization. Analysis Population: ITT Population 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) of first-line treatment ignoring first Central Nervous System (CNS) lesion | 10 / 16 months (PFS will be calculated sustained from randomization until documented PD (ignoring first CNS lesion) or death, whichever occurs first during first-line treatment ) | PFS of first-line treatment ignoring first CNS lesion is the time from randomization to first event progression. A PFS of first-line treatment ignoring first CNS lesion event is defined as (whichever occurs first): * Disease progression (PD) after having received first-line treatment and prior to the next treatment * Death due to any reason Patients without events will be censored at last tumor assessment date without PFS ignoring first CNS lesion event during the first-line treatment period or prior to starting new treatment. Analysis population: ITT Population 1 |
| PFS of second-line treatment | 8 months (PFS will be calculated sustained from registration of second line treatment until documented PD, PD CNS or death, whichever occurs first during second-line treatment) | PFS of second-line treatment is the time from registration of second-line treatment to progression. A PFS event of second-line treatment is defined as (whichever occurs first): * Disease progression after having received second-line treatment and prior to the next treatment * PD CNS after having received first-line treatment and prior to the next treatment * Death due any reason during the second-line treatment period Patients without events will be censored at last tumor assessment date without PD and PD CNS during the second-line treatment period or prior to starting new treatment. Analysis Population: ITT Population 2 |
| PFS of second-line treatment ignoring first CNS lesion | 9 months (PFS will be calculated sustained from registration of second line treatment until documented PD (ignoring first CNS lesion) or death, whichever occurs first during second-line treatment) | PFS of second-line treatment ignoring first CNS lesion is the time from registration of second-line treatment to the first event occurs. A PFS of second-line treatment ignoring first CNS lesion event is defined as (whichever occurs first): * Disease progression after having received second-line treatment and prior to the next treatment * Death due any reason during the second-line treatment period Patients without events will be censored at last tumor assessment date without PFS ignoring first CNS lesion event during the second-line treatment period or prior to starting new treatment. Analysis Population: ITT Population 2 |
| Time to failure of strategy (TFS) of first- plus second-line treatment | 18 / 24 months (TFS will be calculated sustained from randomization until documented PD, PD CNS or death, whichever occurs first before starting third-line therapy ) | TFS of first plus second-line treatment is the time from randomization to TFS event occurs. A TFS event of first plus second-line treatment is defined as (whichever occurs first): * Disease progression after having received the first and second-line treatment and prior to the next treatment * PD CNS after having received first- and second-line treatment and prior to the next treatment * Death due to tumor prior to the third-line treatment Patients without events will be censored at last tumor assessment without PD and PD CNS during first and second-line treatment period or prior to starting new treatment. Analysis Population: ITT Population 1 |
| Overall survival OS | OS will be calculated from randomization until death (estimated median: 32 months) | OS will be calculated from randomization until death. Patients still alive or lost of follow up are censored at their last date known alive. Analysis Population: ITT Population 1 |
| Objective response (OR) of first-line treatment (based on investigator assessment) | 10 / 16 months (OR is defined as the best status of response CR or PR up to first progression or start of a new treatment) | — |
| Disease control (DC) of first-line treatment (based on investigator assessment) | 6 months (DC is defined as CR, PR or SD for 6 months after randomization and no PD at 6 month after randomization) | — |
| OS - Analysis Population: ITT Population 2 | 24 months | Proportion of patients being alive 24 months after randomization. A success is considered if a patient is alive at least 24 months after randomization. Analysis Population: ITT Population 2 |
| DC of second-line treatment (based on investigator assessment) | 6 months (DC is defined as the response CR, PR or SD for 6 months after registration of second-line treatment) | — |
| Adverse events (AEs) according to the NCI CTCAE v4.0 of first-line treatment | Throughout first-line treatment (estimated up to 16 months) | Adverse events are assessed by the NCI CTCAE v4.0. from registration until registration of second-line treatment or start of follow-up (which occurs first). |
| AEs according to the NCI CTCAE v4.0 of second-line treatment | Throughout second-line treatment (estimated up to 9 months) | Adverse events are assessed by the NCI CTCAE v4.0.from second-line registration until PD or start of follow-up (which occurs first) plus 30 days. |
| AEs grade ≥2 until first progression (ignoring first CNS lesion) | Throughout first-line treatment (estimated up to 16 months) | Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until first progression (documented PD, PD CNS or death) |
| Quality of Life (QoL) | At baseline and every 12 weeks (three-monthly) until progression or up to a maximum of 24 months during 1st line therapy. Within 3 weeks prior to registration, after 12 and 24 weeks during 2nd line therapy. | — |
| PFS of third-line treatment | 4 months | PFS will be calculated sustained from start of third-line treatment to progression (PD, PD CNS or death) |
| OR of second-line treatment (based on investigator assessment) | 9 months (OR is defined as the best status of response CR or PR after registration for second-line treatment up to second progression or start of a new treatment) | — |
Countries
France, Germany, Netherlands, Switzerland
Outcome results
None listed